"Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy (Dialysis)"

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

September 13, 2021

Study Completion Date

December 15, 2021

Conditions

Prevention of Thromboembolic Events

Interventions

DRUG

BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5

Tablet, oral

OTHER

BAY2433334 on dialysis treatment day

Tablet, oral

Trial Locations (1)

CRS Clinical-Research-Services Kiel GmbH, Kiel